Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday November 10, 2009

DrStockPick.com Stock Report!

**************************************************************

PowerSafe Technology Corporation (PSFT.PK) subsidiary Amplification Technologies Inc. (www.amplificationtechnologies.com) (ATI), is offering higher performance thermoelectrically cooled discrete amplification single photon counting solid state photodetectors. These photodetectors are mounted on a two stage thermoelectric cooler inside a hermetically sealed TO8 package and can be operated down to a temperature of -30oC.

Glimcher Realty Trust (NYSE: GRT), one of the country’s premier retail REITs today announced the appointment of Ward A. Kampf, as Vice President, Leasing, effective Wednesday, November

...

Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development of their human embryonic stem cell (hESC)-based product, GRNOPC1 which will be used for the treatment of spinal cord injuries. The plan is to let Geron Corporation restart the Phase 1 clinical trial of GRNOPC1 in patients who are suffering from complete thoracic spinal cord injury and to support the future expansion of the clinical trial with patients who are suffering from cervical injuries.

Geron Corporation is one of the developers for the first-in-class biopharmaceuticals that is used for the treatment of cancer and chronic degenerative diseases like spinal cord injury, diabetes and heart failure. GRNOPC1 that is being developed by Geron Corporation is made for the treatment of spinal cord injury but Geron is

...

Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session.

< ?DART(15);?> In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days.

The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000.

Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets.

It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today's Zacks #1 Rank List: Dr. Reddy's Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. (IPXL).

Earnings Estimates

For this year,

...

Recently, Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc. (HUM), announced the availability of an additional benefit for the beneficiaries of the TRICARE program (a medical program under the Department of Defense) in the South Region.  Humana Military Healthcare Services offers health insurance coverage under the TRICARE program to the dependents of active duty military personnel and retired military personnel coupled with their dependents. Humana Military has been a contractor of the Department of Defense for the administration of the TRICARE program since Jul 1, 1996.  The new benefit provides the families of soldiers enrolled in the TRICARE program access to a Chronic Obstructive Pulmonary Disease (COPD) Management Program. They will be able to call a dedicated registered nurse and receive education and coaching on how to deal with this lung disease which blocks airflow thereby resulting in breathing difficulties.  Humana started ...

Health Enhancement Products Inc., in conjunction with Wayne State University and the Wayne State research team, has issued a positive preliminary report on lipid oxidation (oxidative stress) using the company’s ProAlgaZyme filtrates. ProAlgaZyme is a liquid product drawn from living algae grown in purified water.

Oxidative stress is tissue damage resulting from the imbalance between an excessive generation of oxidant compounds and antioxidant defense mechanisms. Oxidative stress, if left unchecked, is believed to be involved in many diseases including: atherosclerosis, heart failure and heart attacks, cancer and Alzheimer’s.

The Wayne State research team is led by Smiti Gupta, Ph.D. who believes the test results are very significant. He summed up the findings as follows, “The test results showed a significant decrease in plasma lipid peroxidation values in a test group of animals given ProAlgaZyme filtrate in their drinking water as compared to the control group given pure water.”

Mr. Gupta continued, “This is

...

Novartis (NVS) is expected to launch its high blood pressure drug Valturna shortly after the recent US Food and Drug Administration approval. The drug is a single-pill combination of Diovan (valsartan), an angiotensin receptor blocker and Tekturna (aliskiren), the only approved direct renin inhibitor. We believe the approval is quite significant as Diovan, one of Novartis’ top-selling drugs with global sales of $5.7 billion in 2008, is losing patent protection in most European Union countries in 2011 and in the U.S. in 2012. Competition is likely to intensify shortly as Merck’s (MRK) Cozaar (2008 sales of $3.5 billion) will lose exclusivity in the U.S. in 2010, bringing in low-priced generics. The approval was based on a randomized, double-blind, placebo-controlled clinical trial on 1800 patients. The trial studied the impact of valsartan (160 mg and 320 mg) and aliskiren (150 mg and 300 mg) independently as ...

The US Food and Drug Administration recently approved Novartis’ (NVS) Valturna for high blood pressure. The drug is a single-pill combination of Diovan (valsartan), an angiotensin receptor blocker, and Tekturna (aliskiren), the only approved direct renin inhibitor.

We believe the approval is quite significant as Diovan, one of Novartis’ top-selling drugs with global sales of $5.7 billion in 2008 is losing patent protection in most European Union countries in 2011 and in the U.S. in 2012. Competition is likely to intensify shortly as Merck’s (MRK) Cozaar (2008 sales of $3.5 billion) will lose exclusivity in the U.S. in 2010, bringing in low-priced generics.

The approval was based on a randomized, double-blind, placebo-controlled clinical trial on 1800 patients. The trial studied the impact of valsartan (160 mg and 320 mg) and aliskiren (150 mg and 300 mg) independently as well as in a combination therapy. It was found

...

Yesterday, Merck (MRK) updated the status of two of its pipeline candidates, both used to treat migraine. While the company abandoned MK-3207, it will continue to develop telcagepant (MK-0974). Although MK-3207 was found to be effective, it caused liver abnormalities in some patients on discontinuing the drug. Due to this, Merck has decided to abandon any further studies of the drug. The phase III trial conducted by Merck for telcagepant found it to be more effective than placebo for acute treatment of multiple migraine attacks. In another study, the safety of the product was compared to another migraine drug of Merck, Maxalt (rizatriptan). The company presented data from both trials at the International Headache Congress and plans to initiate discussions regarding the next steps with the US Food and Drug Administration (FDA) later this year. The telcagepant trial was carried out on 1677 patients who ...

BSX: Positive Results from MADIT Trial Boston Scientific Corporation (BSX) announced positive final results from its landmark MADIT-CRT trial. The MADIT trial was conducted to evaluate the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs).

MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial, engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries.

It is estimated that roughly 22 million people in the world suffer from some form of heart failure, with more than 5.5 million of them being Americans. Class I or II accounted for approximately 70% of all heart failure patients in the U.S. Patients are classified as Class I-II-III-IV by the New York Heart Association based on the degree of symptoms or functional limits, from asymptomatic to bed ridden. 

Major findings in the study were as follows:  

...

For Immediate Release

Chicago, IL – September 1, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Medtronic, Inc. (MDT), St. Jude Medical (STJ), Boston Scientific Corporation (BSX), Baker Hughes, Inc. (BHI) and BJ Services (BJS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

Positive Results for Medtronic

Medtronic, Inc. (MDT) announced positive results from its REVERSE trial, which was designed to evaluate the effectiveness of cardiac resynchronization therapy (CRT) in mildly symptomatic or asymptomatic patients -- that is, those with mild heart failure or patients who previously

...